Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Pancreatic Ductal × Atu027 × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Pancreatic Ductal 1 Adenocarcinoma 1

Interventions

Gemcitabine 15 130-nm albumin-bound paclitaxel 10 Albumin-Bound Paclitaxel 7 Oxaliplatin 5 Paclitaxel 4 Leucovorin 4 Fluorouracil 4 Carboplatin 4 Cisplatin 3 Cetuximab 3 Bevacizumab 3 pembrolizumab 2 napabucasin 2 Pemetrexed 2 PEGPH20 2 MK-4721 2 Irinotecan 2 tremelimumab 1 selinexor 1 relacorilant 1 ponatinib 1 neratinib 1 irinotecan sucrosofate 1 folfirinox 1 ensituximab 1 durvalumab 1 contrast agent BR1 1 cobimetinib 1 ceritinib 1 cc-486 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01808638 2016-03-11

Atu027-I-02

Silence Therapeutics GmbH

Phase 1/2 Completed

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡